MANKIND Q1 FY27 Guidance vs Delivery (MANKIND Management Mirror)

Did MANKIND's management deliver what it guided? Guidance vs actual performance and tone changes across recent earnings calls, as of the Q1 FY27 (Jun-2026 Qtr) concall.

Mankind Pharma Ltd (MANKIND) Q1FY27 Management Mirror - Jun-2026 Qtr

Jun'26 Qtr EBITDA Margin Reported at 26.2%; FY27 Guidance Reaffirmed at 25.5%-26.5% Amid Commodity Cost Pressures

Management's current expectation for FY27 EBITDA margin is 25.5% to 26.5%, with gross margins anticipated upward of 71%, despite projected compression from rising commodity prices and foreign exchange. Chronologically, in the Sep'25 Qtr concall, FY26 EBITDA margin was guided at 25% to 26% (expected at the lower end). This FY26 guidance was reaffirmed during the Dec'25 Qtr concall, with 9M FY26 adjusted EBITDA margin standing at 24.9%. In the Jun'26 Qtr concall, management reaffirmed its FY27 EBITDA margin guidance of 25.5% to 26.5%. For the Jun'26 Qtr, Quarterly Financial Results reported an actual EBITDA margin of 26.2% and EBITDA of INR 1,056 crore.

5 more themes on the ELITE plan.